Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893.
To review of the evidence for the effectiveness of TNF-alpha blocking agents in the maintenance of remission in patients with Crohn’s disease.
Literature review: Searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials and the IBD/FBD Review Group Specialized Trials Register for studies published 1966-2007.
Inclusion criteria: Randomized controlled trials involving patients > 18 years with Crohn’s disease who had a clinical response or clinical remission with a TNF-alpha blocking agent, or patients with Crohn’s disease in remission but unable to wean corticosteroids, who were then randomized to maintenance of remission with a TNF-alpha blocking agent or placebo
Validity criteria: randomization, allocation concealment, blinding, follow-up, intention-to-treat analysis
Assessments of studies: independent review by each of the two authors; resolution of disagreement by consensus of the two
Analysis 1.4 shows the risk ratio for fistula healing, comparing placebo to infliximab.